OCA
AUTL icon

Octagon Capital Advisors’s Autolus Therapeutics AUTL Stock Holding History

Octagon Capital Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-176,000
Closed -$639K – 35
2024
Q3 		$639K Hold
176,000
– – 0.1% 39
2024
Q2 		$612K Hold
176,000
– – 0.1% 46
2024
Q1 		$1.12M Buy
+176,000
New +$1.1M 0.13% 56

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Octagon Capital Advisors's AUTL Position: Q4 2024 in Review

Octagon Capital Advisors sold out of Autolus Therapeutics (AUTL) in Q4 2024, closing a stake of 176,000 shares — an estimated $639K sold.

Octagon Capital Advisors first reported a position in AUTL in Q1 2024 and held it in 3 quarters. The position peaked at $1.12M in Q1 2024. 110 funds tracked by Wall St. Rank hold AUTL as of Q4 2024.

  • Octagon Capital Advisors reported no remaining Autolus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 176,000 Autolus Therapeutics shares in Q4 2024, an estimated $639K.
  • Octagon Capital Advisors first reported a position in Autolus Therapeutics in Q1 2024 and held it in 3 quarters.
  • Octagon Capital Advisors's Autolus Therapeutics position peaked at $1.12M in Q1 2024.
  • 110 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2024.

Based on Octagon Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.